First and only antibody for Multiple Myeloma approved in EU

13/05/2016 - 3 minutes

Bristol-Myers Squibb and AbbVie have announced that their co-development project for an antibody therapy against Multiple Myeloma has been approved in the EU after a successful Phase III trial.

bms_abbvie_multiple_myeloma_eloquent_antibody_elotuzumav_emplicitiEmpliciti (elotuzumab) has been developed for the treatment of multiple myeloma as combination therapy in patients who have received at least one prior therapy, now making it the first and only immunostimulatory antibody approved for multiple myeloma in the EU.

The approval is based on data from the Phase III ELOQUENT-2 study, which evaluated Empliciti in combination with the thalidomide dervivate lenalidomide and the steroid dexamethasone. The trial ran for 646 patients in total across Europe as well as Australia, Japan and Russia.

empliciti_elotuzumab_bms_abbvie_multiple_myeloma_lenalidomide_dexamethasone

Empliciti has a dual mechanism-of-action. It directly activates the immune system through Natural Killer cells via the SLAMF7 pathway. Empliciti also targets SLAMF7 on myeloma cells, tagging these malignant cells for Natural Killer cell-mediated destruction via antibody-dependent cellular toxicity.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member